Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Keros Therapeutics (KROS) Other Non Operating Income (2019 - 2025)

Keros Therapeutics filings provide 7 years of Other Non Operating Income readings, the most recent being $273000.0 for Q4 2025.

  • On a quarterly basis, Other Non Operating Income rose 219.21% to $273000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$539000.0, a 43.5% increase, with the full-year FY2025 number at -$539000.0, up 43.5% from a year prior.
  • Other Non Operating Income hit $273000.0 in Q4 2025 for Keros Therapeutics, up from -$253000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $762000.0 in Q3 2022 to a low of -$1.4 million in Q4 2022.
  • Median Other Non Operating Income over the past 5 years was -$96500.0 (2021), compared with a mean of -$134750.0.
  • The widest YoY moves for Other Non Operating Income: up 656.2% in 2022, down 1288.12% in 2022.
  • Keros Therapeutics' Other Non Operating Income stood at -$101000.0 in 2021, then tumbled by 1288.12% to -$1.4 million in 2022, then soared by 103.99% to $56000.0 in 2023, then crashed by 508.93% to -$229000.0 in 2024, then soared by 219.21% to $273000.0 in 2025.
  • The last three reported values for Other Non Operating Income were $273000.0 (Q4 2025), -$253000.0 (Q3 2025), and -$221000.0 (Q2 2025) per Business Quant data.